Literature DB >> 12804141

Antibody-mediated targeting of replication-competent retroviral vectors.

Chien-Kuo Tai1, Christopher R Logg, Jinha M Park, W French Anderson, Michael F Press, Noriyuki Kasahara.   

Abstract

Replication-competent murine leukemia virus (MLV) vectors can be engineered to achieve high efficiency gene transfer to solid tumors in vivo and tumor-restricted replication, however their safety can be further enhanced by redirecting tropism of the virus envelope. We have therefore tested the targeting capability and replicative stability of ecotropic and amphotropic replication-competent retrovirus (RCR) vectors containing two tandem repeats from the immunoglobulin G-binding domain of Staphylococcal protein A inserted into the proline-rich "hinge" region of the envelope, which enables modular use of antibodies of various specificities for vector targeting. The modified envelopes were efficiently expressed and incorporated into virions, were capable of capturing monoclonal anti-HER2 antibodies, and mediated efficient binding of the virus-antibody complex to HER2-positive target cells. While infectivity was markedly reduced by pseudotyping with targeted envelopes alone, coexpression of wild-type envelope rescued efficient cellular entry. Both ecotropic and amphotropic RCR vector/anti-HER2 antibody complexes achieved significant enhancement of transduction on murine target cells overexpressing HER2, which could be competed by preincubation with excess free antibodies. Interestingly, HER2-expressing human breast cancer cells did not show enhancement of transduction despite efficient antibody-mediated cell surface binding, suggesting that target cell-specific parameters markedly affect the efficiency of post-binding entry processes. Serial replication of targeted vectors resulted in selection of Z domain deletion variants, but reduction of the overall size of the vector genome enhanced its stability. Application of antibody-mediated targeting to the initial localization of replication-competent virus vectors to tumor sites will thus require optimized target selection and vector design.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804141     DOI: 10.1089/104303403765255174

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  20 in total

Review 1.  Viruses as anticancer drugs.

Authors:  Stephen J Russell; Kah-Whye Peng
Journal:  Trends Pharmacol Sci       Date:  2007-06-18       Impact factor: 14.819

2.  Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus.

Authors:  S Kubo; M Takagi-Kimura; C R Logg; N Kasahara
Journal:  Cancer Gene Ther       Date:  2013-11-08       Impact factor: 5.987

3.  Antibody-mediated targeted gene transfer of helper virus-free HSV-1 vectors to rat neocortical neurons that contain either NMDA receptor 2B or 2A subunits.

Authors:  Haiyan Cao; Guo-rong Zhang; Alfred I Geller
Journal:  Brain Res       Date:  2011-08-11       Impact factor: 3.252

4.  Efficient gene transfers into neocortical neurons connected by NMDA NR1-containing synapses.

Authors:  Aarti Nagayach; Anshuman Singh; Alfred I Geller
Journal:  J Neurosci Methods       Date:  2019-08-09       Impact factor: 2.390

5.  Antibody-mediated targeted gene transfer to NMDA NR1-containing neurons in rat neocortex by helper virus-free HSV-1 vector particles containing a chimeric HSV-1 glycoprotein C-staphylococcus A protein.

Authors:  Haiyan Cao; Guo-Rong Zhang; Alfred I Geller
Journal:  Brain Res       Date:  2010-06-28       Impact factor: 3.252

6.  Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.

Authors:  Chien-Kuo Tai; Wei Jun Wang; Thomas C Chen; Noriyuki Kasahara
Journal:  Mol Ther       Date:  2005-11       Impact factor: 11.454

7.  Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.

Authors:  C-K Tai; W Wang; Y-H Lai; C R Logg; W B Parker; Y-F Li; J S Hong; E J Sorscher; T C Chen; N Kasahara
Journal:  Cancer Gene Ther       Date:  2010-05-14       Impact factor: 5.987

Review 8.  Library screening and receptor-directed targeting of gammaretroviral vectors.

Authors:  Peter M Mazari; Monica J Roth
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

Review 9.  Cellular and vaccine therapeutic approaches for gliomas.

Authors:  Michelle J Hickey; Colin C Malone; Kate L Erickson; Martin R Jadus; Robert M Prins; Linda M Liau; Carol A Kruse
Journal:  J Transl Med       Date:  2010-10-14       Impact factor: 5.531

10.  Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations.

Authors:  María Mercedes Segura; Alain Garnier; Marcos Rafael Di Falco; Gavin Whissell; Angélica Meneses-Acosta; Normand Arcand; Amine Kamen
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.